The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment
agents that combines the selectivity of targeted treatment with the cytotoxic potency of …

The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly
due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the …

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-
2 ligand (Apo2L), is a member of the TNF cytokine superfamily. By cross-linking TRAIL …

Highlights•ADC represents a new class of targeted anticancer therapeutics.•Elucidates
selection criteria for tumor specific antigen and ADC development.•Smart linkers and fixed …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …

Monoclonal antibodies (mAbs) are an important class of therapeutic agents approved for the
therapy of many types of malignancies. However, in certain cases applications of …

Major advances in therapeutic proteins, including antibody–drug conjugates (ADCs), have
created revolutionary drug delivery systems in cancer over the past decade. While these …

Over the recent decades, the use of antibody–drug conjugates (ADCs) has led to a
paradigm shift in cancer chemotherapy. Antibody–based treatment of various human tumors …

Unconjugated monoclonal antibodies that target hematopoietic differentiation antigens have
been developed to treat hematologic malignancies. Although some of these have activity …